ARWR News

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO ® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals annonce l’approbation de REDEMPLO MC (plozasiran) par Santé Canada pour réduire les triglycérides chez les adultes atteints du syndrome de chylomicronémie familiale (SCF)

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences